Pharmaceuticals News

On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind,...

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation...

PHILADELPHIA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies...

- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultural voices anchors community education nationwide PALO ALTO, Calif., Oct. 05, 2026 (GLOBE...

STONY BROOK, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- iCell Gene Therapeutics ("iCell Gene"), a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for...

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling...

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Click Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance (marketing authorization) for...

Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically...

Company announcement No. 53 / 2026 Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S...